Full Press Release Details
| Dr. Reddy's Laboratories Ltd. | |
| 8-2-337, Road No. 3, Banjara Hills, | |
| Hyderabad - 500 034, Telangana, | |
| India. | |
| CIN: L85195TG1984PLC004507 | |
| Tel : +91 40 4900 2900 | |
| Fax : +91 40 4900 2999 | |
| Email : mail@drreddys.com | |
| www.drreddys.com |
| Corporate Relationship Department | National Stock Exchange of India Ltd. |
| BSE Limited | "Exchange Plaza" |
| Dalal Street, Fort | Bandra-Kurla Complex, Bandra (East), |
| Mumbai - 400 001 | Mumbai - 400 051 |
| Fax Nos.: 022-22723121 / 22723719 | Fax Nos.: 022-26598120/ 26598237 |
| Scrip Code: 500124 | Scrip Code: DRREDDY-EQ |
This is to inform you that we have
received the Establishment Inspection Report (BIR) from US FDA, for our Formulations Manufacturing Plant - 3 at Bachupally,
In February, 2019 this site has undergone
an audit by the US FDA, wherein we were issued a Form 483 with 11 (eleven) observations. Based on our responses and follow up actions,
the US FDA has determined the inspection classification of this facility as Voluntary Action Initiated (VAI).
This is for your information.
| Vikas Sabharwal | |
| Assistant Company Secretary |
CC:- New York Stock Exchange Inc.(Stock Code :RDY)